# China NMPA Inspection - Jilin Taiyu Pharmaceutical Technology Co., Ltd. - June 07, 2022

Source: https://www.keypedia.com/records/china_inspection/jilin-taiyu-pharmaceutical-technology-co-ltd/a33fbd34-67f2-4164-a5da-d9f3023356fe
Source feed: China

> China NMPA unannounced inspection for Jilin Taiyu Pharmaceutical Technology Co., Ltd. published June 07, 2022. On June 7, 2022, the Jilin Provincial Drug Administration announced its proposal to grant a Cosmetics Production License to Jilin Taiyu Pharmaceutical

---

## Details

- Record Type: CHINA_INSPECTION
- Title: Jilin Provincial Drug Administration's Notice on the Proposed Issuance of Cosmetic Production Licenses (2022, Issue 2)
- Company Name: Jilin Taiyu Pharmaceutical Technology Co., Ltd.
- Publication Date: 2022-06-07
- Product Type: cosmetics
- Summary: On June 7, 2022, the Jilin Provincial Drug Administration announced its proposal to grant a Cosmetics Production License to Jilin Taiyu Pharmaceutical Technology Co., Ltd. This significant step follows a thorough on-site inspection and subsequent approval, conducted in adherence to the former State Food and Drug Administration's "Notice on Further Improving Current Work Related to Cosmetics Production Licensing." The inspection, which occurred before this public announcement, affirmed that Jilin Taiyu Pharmaceutical Technology Co., Ltd. meets the necessary standards for cosmetics production. The license, once finalized, will permit the company to manufacture general liquid unit, and cream and emulsion unit cosmetics at its facility located on the First Floor, North Side of Building 4, Science and Technology Incubation Park, Changchun Xinglong Comprehensive Bonded Zone. This regulatory action underscores the provincial administration's commitment to ensuring the quality and safety of cosmetic products within its jurisdiction. As part of the transparent licensing process, the public is invited to provide supervision and feedback on this proposed issuance for a period of five working days. This public comment phase allows for external oversight, reinforcing accountability in the regulatory approval process. Importantly, the document indicates a successful inspection, with no violations or issues reported, signaling the company's readiness to operate under stringent cosmetic production guidelines.

Company: https://www.keypedia.com/companies/jilin-taiyu-pharmaceutical-technology-co-ltd/5ff41772-be49-4e71-8d3c-f011bd4d8655